**MONDAY, AUGUST 17**

**Keynote Address**

James P. Allison, University of Texas MD Anderson Cancer Center, USA  
**Immune Checkpoint Blockade in Cancer Therapy: New Insights into Therapeutic Mechanisms**

**Mechanisms of Action I**

*Ira Mellman*, Genentech, Inc., USA  
**Mechanistic Basis of Cancer Immunotherapy**

*Kelli Connolly*, Yale University, USA  
**Short Talk: Tumor-Draining Lymph Nodes Contain an Untapped Reservoir of Stem-Like CD8 T Cells**

**AHyun Choi**, Novartis Institutes for BioMedical Research, USA  
**Short Talk: Loss of EMC Inhibits Tumor Growth through Enhanced Adaptive Immune Response**

**Mechanisms of Action II**

Jane Oliaro, Peter MacCallum Cancer Centre, Australia  
**Identifying New Targets for Cancer Immunotherapy**

Vandana Kalia, University of Washington and Seattle Children’s Research Institute, USA  
**Short Talk: PD-1 Signals Are Critical for Maintenance of CD8 T Cell Memory**

**Katie Campbell**, University of California, Los Angeles, USA  
**Short Talk: Integrating DNA and RNA Sequencing Analysis to Describe Somatic Alterations and Expression in the HLA Gene Loci**

**Stephen Mok**, MD Anderson Cancer Center, USA  
**Short Talk: Late Interferon-Gamma Blockade Improves Antitumor Efficacy of Anti-CTLA-4 and Anti-PD-1 Combination Treatment**

**Mechanisms of Response I**

*Siwen Hu-Lieskovann*, Huntsman Cancer Institute, USA  
**Clinical Testing Strategies against Heterogenous Mechanisms of Immune Resistance**

**Antoni Ribas**, University of California, Los Angeles, USA  
**Mechanisms of Primary and Acquired Resistance to PD-1 Blockade Therapy**

**Chang Liu**, University of Pittsburgh, USA  
**Short Talk: Neurupilin-1 Is a T Cell Memory Checkpoint Limiting Long-Term Anti-Tumor Immunity**

**Mechanisms of Response II**

Padmanee Sharma, University of Texas MD Anderson Cancer Center, USA  
**From the Clinic to the Lab: Investigating Mechanisms of Response and Resistance to Immune Checkpoint Therapy**

*Yuxuan Miao*, Rockefeller University, USA  
**Short Talk: Adaptive Immune Resistance Emerges From Tumor-Initiating Stem Cells**

Shira Tabachnick-Cherny, University of Washington, USA  
**Short Talk: Characterization of Myeloid Cells Subsets in the Tumor Microenvironment of Merkel Cell Carcinoma**

Zoila Areli Lopez Bujanda, Johns Hopkins University, USA  
**Short Talk: ADT-Mediated Intra-Tumoral Myeloid Infiltration Promotes Resistance to Immune Checkpoint Blockade in Prostate Cancer**

**Poster Session**

**TUESDAY, AUGUST 18**

**Therapeutic Play I**

Yvonne Y. Chen, University of California, Los Angeles, USA  
**Engineering Next-Generation CAR-T Cell Therapy for Cancer**

*Juan C. Jaen*, Arcus Biosciences, Inc., USA  
**Clinical Applications of Adenosine Pathway Inhibitors**

Coralie Backlund, Massachusetts Institute of Technology, USA  
**Short Talk: Cell Penetrating Peptides Improve T Cell Response to Neoantigen Peptide Vaccines**

Majia Holmén, University of Turku, Finland  
**Short Talk: Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumours**

Yingxiao Wang, University of California, San Diego, USA  
**Short Talk: Engineering Remotely Controllable CAR T Cells for Cancer Immunotherapy**

**Therapeutic Play II**

*Evan Scott*, Northwestern University, USA  
**Engineered Nanobiomaterials for Cancer Immunotherapy**

E. John Wherry, University of Pennsylvania, USA  
**Epigenetic Features of Exhausted Antitumor T Cells**

Buvana Ravishankar, Rapt Therapeutics, Inc., USA  
**Short Talk: Targeting the Stress Response Kinase GCN2 Potentiates Anti-Tumor Immune Response**

Anthony K. Park, City of Hope, USA  
**Short Talk: Effective Combination Immunotherapy using Oncolytic Viruses to Deliver CAR Targets to Solid Tumors**

Patrick A. Ott, Dana-Farber Cancer Institute, USA  
**Short Talk: Personal Neoantigen Vaccines Induce Long-term Immune Responses in Patients with High Risk Melanoma**

**Genomics of Cancer I**

*Priti Hegde*, Foundation Medicine, USA  
**Pan-Cancer Analysis of Allele-Specific HLA-I Loss Suggests Widespread Occurrence across a Diverse Range of Tumor Types**

Eliezer M. Van Allen, Dana-Farber Cancer Institute, USA  
**Tumor Genomics and Selective Response to Cancer Immunotherapy**

*Nadine A. Defranoux*, Parker Institute for Cancer Immunotherapy, USA  
**Short Talk: Strategies to Improve the Sensitivity and Ranking Ability of Neoantigen Prediction Methods: Report on the Results of the Tumor nEoantigen SeLection Alliance (TESLA)**

Gloria Bora Kim, University of Pennsylvania, USA  
**Short Talk: Splice Variants as Neoantigens for Cancer Immunotherapy**

*Session Chair † Invited but not yet accepted Program current as of August 15, 2020. Program subject to change. Meal formats are based on meeting venue. For the most up-to-date details, visit https://www.keystonesymposia.org.*
Genomics of Cancer II

Elaine R. Mardis, Nationwide Children's Hospital, USA
*Immunogenomics and the TME in Pediatric CNS Cancers*

Thomas D. Wu, Genentech, Inc., USA
*Short Talk: Peripheral T Cell Expansion Predicts Tumor Infiltration and Clinical Response to Cancer Immunotherapy*

Debattama Sen, Harvard Medical School, USA
*Short Talk: Disrupting Enhancers within the Core Epigenetic Program of Exhaustion Improves CD8+ T Cell Responses and Enhances Tumor Control*

WEDNESDAY, AUGUST 19

Single Cell I

James R. Heath, Institute for Systems Biology, USA
*Single Cell Approaches to Analyzing Antitumor Responses*

*Ansuman Satpathy, Stanford University School of Medicine, USA
*Single-Cell Genomics in Cancer Immunotherapy*

Christine Carine Moussion, Genentech, Inc., USA
*Short Talk: Local Heterogeneity of Response to CIT: Learning from the STAMP Live Imaging Model*

James C. Lee, University of California, San Francisco, USA
*Short Talk: Liver Metastasis Mediated Control of Systemic Tumor-Specific Immunity and Response to Checkpoint Immunotherapy*

Single Cell II

*Sohail F. Tavazoie, Rockefeller University, USA
*Depleting Myeloid-Suppressive Cells for Cancer Immunotherapy*

Theodore Roth, University of California, San Francisco, USA
*Short Talk: Parallel Engineering of Immune Cell Genomes by Pooled Knockin Targeting*

Amanda Oliver, Peter MacCallum Cancer Centre, Australia
*Short Talk: Tissue-Specific Tumour Microenvironments Influence Responses to Immunotherapy*